Basma Adeem Medical company (9626) fair value: what the stock is really worth
As of Oct 14, 2026: fair value of Basma Adeem Medical company SAR 13.39, price SAR 6.20, upside +116.0%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 3, 2026.
How to read this chart
10‑month range 5.18 SAR – 7.00 SAR · fair‑value band 8.95 SAR – 17.40 SAR · the 6.20 SAR price screens below the 13.39 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 3, 2026.
Follow Basma Adeem Medical in your weekly email
Every Wednesday you see whether Basma Adeem Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Basma Adeem Medical company provides dental services in the Kingdom of Saudi Arabia.
Show moreShow less
Its services include same day surgery; dermatology and laser; dental repair, restorations, and cosmetic dentistry; gum surgery and dental implant; root canal treatment; oral and dental health; pediatric dentistry; and maxillofacial surgery, as well as orthodontic treatment for dental, face, and jaw surgery.
Basma Adeem Medical company was incorporated in 2012 and is headquartered in Riyadh, the Kingdom of Saudi Arabia.
Stock analysis
Basma Adeem Medical company (9626) currently trades at 6.20 SAR, while our model-based Fair Value estimate is 13.39 SAR, implying the stock looks roughly 53.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 16.73 SAR per share, and 19 of the 23 models we run sit above the 6.20 SAR price.
Bear case: the Economic Profit group reads lowest at 3.09 SAR, and 4 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 8.95 SAR (bear) to 17.40 SAR (bull), the price of 6.20 SAR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Basma Adeem Medical company reported revenue of 45.5M SAR in FY2025 versus 21.9M SAR in FY2022, a compound +27.5%/yr. Reported net income was 7.3M SAR in FY2025, compounding +24.5%/yr from FY2022.
Key figures
Market cap 122M SAR (≈ $32.5M) · P/E ratio 11.9 · P/S ratio 1.92 · EPS (TTM) 0.5200 SAR · Net margin 16.1% · Return on equity 20.7% · Return on assets (EBIT) 36.6% · Operating margin 16.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 69 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 20% fair-value upside, at 116%, 9626 screens cheaper than that median.
Fair Value models
Bear8.95 SARFair Value 13.39 SARBull17.40 SAR
Price 6.20 SAR · Upside +116.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.4117 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+34.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.5%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+28.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+28.9%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 18%
2025 sits 66% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Saudi Arabia: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −7.6% a year for the price.
Compare Basma Adeem Medical company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 243 stocks
Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+116.0% · Top 25%
Profitability
Return on equity (12 months)20.7% · Top 25%
Return on assets11.0% · Top 25%
Net margin (12 months)17.4% · Top 25%
Operating margin (12 months)16.3% · Top 25%
Growth and dividend
Revenue growth50.4% · Top 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Basma Adeem Medical company Fair Value". https://www.fairvalue-calculator.com/stock/9626
Frequently asked questions
Is Basma Adeem Medical company (9626) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 13.39 SAR versus a price of 6.20 SAR, about +116% upside (undervalued).
What is the fair value of 9626?
Our model-based fair value for Basma Adeem Medical company is 13.39 SAR (as of Oct 3, 2026), built from audited fundamentals. The current price: 6.20 SAR.
What is the quality score of 9626?
Basma Adeem Medical company has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Basma Adeem Medical company (9626)?
Our model-based price target is the fair value of 13.39 SAR (as of Oct 3, 2026) from 23 valuation models. Cautious scenario 8.95 SAR, optimistic scenario 17.40 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Basma Adeem Medical company stock forecast for 2026?
Our models put fair value at 13.39 SAR, about +116% upside versus a price of 6.20 SAR (undervalued). Cautious scenario 8.95 SAR, optimistic scenario 17.40 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Basma Adeem Medical company (9626)?
Basma Adeem Medical company reported trailing-twelve-month revenue of about 54.9M SAR (latest available figure, as of Oct 3, 2026).
What growth is priced into Basma Adeem Medical company (9626)?
For today's price to be fair in a discounted-cash-flow model, Basma Adeem Medical company would have to grow free cash flow by -5.7 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +27.5 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of 9626 use?
Our models discount Basma Adeem Medical company at 10.3 %: a base by market capitalisation (nano), country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Basma Adeem Medical company that is -5.7 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Basma Adeem Medical company (9626) delivered so far?
Over the past 3 years revenue at Basma Adeem Medical company grew +27.5 % a year. The price currently implies -5.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Basma Adeem Medical company (9626) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Basma Adeem Medical company (-5.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Basma Adeem Medical company (9626)?
The free-cash-flow yield on the price is 10.16 %: that much free cash flow Basma Adeem Medical company produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Basma Adeem Medical company (9626)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Basma Adeem Medical company it is 13.39 SAR per share (as of Oct 3, 2026), against a price of 6.20 SAR. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Basma Adeem Medical company stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 9626 trades below its calculated fair value: price 6.20 SAR, fair value 13.39 SAR, a gap of about +116% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9626?
No. The price is what the market pays today (6.20 SAR); the fair value is what the company's own numbers justify (13.39 SAR). For Basma Adeem Medical company the two are 7.19 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Basma Adeem Medical company worth?
The market values Basma Adeem Medical company at about 122M SAR (market capitalisation, as of Oct 3, 2026). Per share that is 6.20 SAR; our models calculate a fair value of 13.39 SAR per share.
What do the bullish and bearish scenarios say about 9626?
Our models span a range for Basma Adeem Medical company: cautious scenario 8.95 SAR, base 13.39 SAR, optimistic 17.40 SAR per share (as of Oct 3, 2026, price 6.20 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9626?
Basma Adeem Medical company trades at a price-to-earnings ratio of 11.9 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 13.39 SAR is built from several models across several years. Other multiples: P/B 3.4, P/S 2.2, EV/EBITDA 7.4.
How solid is the balance sheet of Basma Adeem Medical company (9626)?
Balance-sheet figures for Basma Adeem Medical company (as of Oct 3, 2026): return on equity 20.7%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
Which stocks are comparable to Basma Adeem Medical company?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Basma Adeem Medical company stock attractive at the current price?
The data as of Oct 3, 2026: price 6.20 SAR, calculated fair value 13.39 SAR (+116%), Quality Score 68/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9626 calculated?
We run Basma Adeem Medical company through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 13.39 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Basma Adeem Medical company currently trades 54 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Basma Adeem Medical company (9626)?
The closing price on Oct 14, 2026 was 6.20 SAR. Our model-based fair value is 13.39 SAR, about +116% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Basma Adeem Medical company right now?
The price is below even our cautious bear case (8.95 SAR). The market is more pessimistic than our downside scenario. Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (8.95 SAR to 17.40 SAR) leaves room in how you read the outcome.
Key figures of Basma Adeem Medical company
How large is the market capitalisation of Basma Adeem Medical company (9626)?
The market capitalisation of Basma Adeem Medical company is 122M SAR (≈ $32.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Basma Adeem Medical company (9626)?
The price-to-sales ratio of Basma Adeem Medical company is 1.92 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Basma Adeem Medical company (9626)?
Earnings per share at Basma Adeem Medical company are 0.5200 SAR (price ÷ EPS = P/E 11.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Basma Adeem Medical company (9626)?
The net margin of Basma Adeem Medical company is 16.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Basma Adeem Medical company (9626)?
The return on equity (ROE) of Basma Adeem Medical company is 20.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Basma Adeem Medical company (9626)?
On an EBIT basis the return on assets of Basma Adeem Medical company is 36.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Basma Adeem Medical company (9626)?
The operating margin of Basma Adeem Medical company is 16.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Basma Adeem Medical company (9626)?
Revenue at Basma Adeem Medical company is growing +50.4% versus a year earlier (3y avg +27.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Basma Adeem Medical company (9626)?
Earnings per share at Basma Adeem Medical company are growing +100% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Basma Adeem Medical company (9626) hold?
Basma Adeem Medical company holds more cash than debt, 8.3M SAR net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Basma Adeem Medical company in the live analysis
One click puts Basma Adeem Medical company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Some data
Oct 3, 2026